Recent Evidence on Cardiac 99m Tc-DPD Uptake After Therapy with Tafamidis May Reveal the Road to an Ultra-Early Diagnosis in Patients with ATTR Amyloidosis
Journal of Nuclear Medicine · 2024
DOI: 10.2967/jnumed.123.266676 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Federico Caobelli. Hauptthemen laut MEDLINE: Amyloidosis, Cardiomyopathies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
TO THE EDITOR: In recent years, the management of patients with amyloid transthyretin–related (ATTR) cardiac amyloidosis (CA) has undergone major changes because of the validation of effective therapies. For example, new treatment with antibodies such as N1006 showed promise in depleting ATTR CA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Caobelli, F. (2024). Recent Evidence on Cardiac 99m Tc-DPD Uptake After Therapy with Tafamidis May Reveal the Road to an Ultra-Early Diagnosis in Patients with ATTR Amyloidosis. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.266676
Vancouver
Caobelli F. Recent Evidence on Cardiac 99m Tc-DPD Uptake After Therapy with Tafamidis May Reveal the Road to an Ultra-Early Diagnosis in Patients with ATTR Amyloidosis. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.266676
BibTeX
@article{Caobelli2024,
author = {Caobelli, Federico},
title = {Recent Evidence on Cardiac 99m Tc-DPD Uptake After Therapy with Tafamidis May Reveal the Road to an Ultra-Early Diagnosis in Patients with ATTR Amyloidosis},
journal = {Journal of Nuclear Medicine},
year = {2024},
doi = {10.2967/jnumed.123.266676}
}
EUVIMED